[go: up one dir, main page]

CY1110928T1 - Παραγωγα διαζεπανης-ακεταμιδης ως εκλεκτικοι 11-usd1 αναστολεις - Google Patents

Παραγωγα διαζεπανης-ακεταμιδης ως εκλεκτικοι 11-usd1 αναστολεις

Info

Publication number
CY1110928T1
CY1110928T1 CY20101100725T CY101100725T CY1110928T1 CY 1110928 T1 CY1110928 T1 CY 1110928T1 CY 20101100725 T CY20101100725 T CY 20101100725T CY 101100725 T CY101100725 T CY 101100725T CY 1110928 T1 CY1110928 T1 CY 1110928T1
Authority
CY
Cyprus
Prior art keywords
diazepanis
aketamidis
usd1
electors
inhibitions
Prior art date
Application number
CY20101100725T
Other languages
English (en)
Inventor
Denis Carniato
Caroline Leriche
Didier Roche
Christine Charon
Liliane Doare
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CY1110928T1 publication Critical patent/CY1110928T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε παράγωγα διαζεπάνης- ακεταμίδης του χημικού τύπου I ως αναστολείς του ενζύμου 11-βήτα- υδροξυστεροειδικής δεϋδρογενάσης τύπου 1 (11β-HSDI) και στην χρήση τέτοιων ενώσεων για την αντιμετώπιση και την πρόληψη του μεταβολικού συνδρόμου, του διαβήτη, της αντοχής στην γλυκόζη, της παχυσαρκίας, των διαταραχών των λιπιδίων, του γλαυκώματος, της οστεοπόρωσης, των γνωσιακών δυσλειτουργιών, του άγχους, της κατάθλιψης, των ανοσολογικών διαταραχών, της υπέρτασης και άλλων ασθενειών και καταστάσεων.
CY20101100725T 2006-11-03 2010-08-03 Παραγωγα διαζεπανης-ακεταμιδης ως εκλεκτικοι 11-usd1 αναστολεις CY1110928T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06291704A EP1918285A1 (en) 2006-11-03 2006-11-03 Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors
EP07818740A EP2078001B8 (en) 2006-11-03 2007-10-05 Diazepane-acetamide derivatives as selective 11 -hsd1 inhibitors

Publications (1)

Publication Number Publication Date
CY1110928T1 true CY1110928T1 (el) 2015-06-10

Family

ID=38462005

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100725T CY1110928T1 (el) 2006-11-03 2010-08-03 Παραγωγα διαζεπανης-ακεταμιδης ως εκλεκτικοι 11-usd1 αναστολεις

Country Status (16)

Country Link
US (2) US8242107B2 (el)
EP (2) EP1918285A1 (el)
JP (1) JP5538892B2 (el)
AR (1) AR063454A1 (el)
AT (1) ATE467623T1 (el)
AU (1) AU2007315307B2 (el)
CA (1) CA2668504C (el)
CY (1) CY1110928T1 (el)
DE (1) DE602007006535D1 (el)
DK (1) DK2078001T3 (el)
ES (1) ES2345296T3 (el)
IL (1) IL198462A (el)
PL (1) PL2078001T3 (el)
PT (1) PT2078001E (el)
SI (1) SI2078001T1 (el)
WO (1) WO2008052638A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
RU2470017C2 (ru) 2007-06-08 2012-12-20 Янссен Фармацевтика Н.В. Производные пиперидина/пиперазина
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2725933C (en) 2008-06-05 2018-01-16 Janssen Pharmaceutica Nv Drug combinations comprising a dgat inhibitor and a ppar-agonist
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103951624B (zh) * 2010-08-26 2019-04-16 兴和株式会社 1,4-二氮杂环庚烷衍生物或其盐的制造方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1087491A (ja) * 1996-07-26 1998-04-07 Asahi Chem Ind Co Ltd 転写調節因子阻害剤
EP0975659A1 (en) * 1997-04-14 2000-02-02 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998046591A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
KR20050051691A (ko) * 2002-10-11 2005-06-01 아스트라제네카 아베 1,4-이치환 피페리딘 유도체 및 11-베타ｈｓｄ1억제제로서의 이들의 용도
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
CA2548309A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Aryl sulfonamide compounds and uses related thereto
NZ551603A (en) * 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
CA2598610C (en) * 2005-03-03 2011-05-31 F. Hoffmann-La Roche Ag 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus

Also Published As

Publication number Publication date
DE602007006535D1 (de) 2010-06-24
ES2345296T3 (es) 2010-09-20
DK2078001T3 (da) 2010-07-19
US20100069365A1 (en) 2010-03-18
AR063454A1 (es) 2009-01-28
EP2078001B8 (en) 2010-12-15
CA2668504A1 (en) 2008-05-08
IL198462A (en) 2014-12-31
CA2668504C (en) 2015-06-30
PL2078001T3 (pl) 2010-11-30
JP5538892B2 (ja) 2014-07-02
AU2007315307A1 (en) 2008-05-08
EP2078001B1 (en) 2010-05-12
AU2007315307B2 (en) 2013-05-09
SI2078001T1 (sl) 2010-07-30
US8586577B2 (en) 2013-11-19
US20120283247A1 (en) 2012-11-08
IL198462A0 (en) 2010-02-17
WO2008052638A1 (en) 2008-05-08
US8242107B2 (en) 2012-08-14
PT2078001E (pt) 2010-08-18
EP1918285A1 (en) 2008-05-07
ATE467623T1 (de) 2010-05-15
EP2078001A1 (en) 2009-07-15
JP2010508312A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
CY1110928T1 (el) Παραγωγα διαζεπανης-ακεταμιδης ως εκλεκτικοι 11-usd1 αναστολεις
EA200801426A1 (ru) ПРОИЗВОДНЫЕ 2-АДАМАНТИЛМОЧЕВИНЫ В КАЧЕСТВЕ СЕЛЕКТИВНЫХ ИНГИБИТОРОВ 11β-HSD1
CY1113645T1 (el) Παραγωγα 7-αζαϊνδολης ως επιλεκτικοι αναστολεις 11-βητα-υδροξυστεροειδους δεϋδρογενασης τυπου 1
EA201300759A1 (ru) Новые производные nip тиазола в качестве ингибиторов 11-бета-гидроксистероид дегидрогеназы-1
IL213425A0 (en) Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
EA200870462A1 (ru) Производные бифениламидлактама в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1
EA200970088A1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
MX347145B (es) Derivados de adamantilo-acetamida como inhibidores de la enzima tipo i de 11-beta-hidroxiesteroide deshidrogenasa.
ATE556050T1 (de) Inhibitoren des 11-beta-hydroxysteroid- dehydrogenase-1-enzyms
MX2007008239A (es) Inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
MA34916B1 (fr) Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
ATE471311T1 (de) Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
WO2010036613A8 (en) Novel cyclic benzimidazole derivatives useful anti-diabetic agents
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
EA200800081A1 (ru) Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
DE602006010564D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
DK2049513T3 (da) Piperidinylsubstituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
CY1110753T1 (el) Αναστολεις της 11-βητα-υδροξυστεροειδους αφυδρογονασης i
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
EA200970170A1 (ru) Производные 4-триметиламмоний-3-аминобутирата и 4-триметилфосфоний-3-аминобутирата как ингибиторы срт
WO2008042921A3 (en) Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use
EA201100419A1 (ru) Сопряженные пирролидино-циклопропановые производные в качестве селективных ингибиторов 11-бета-гидроксистероид дегидрогеназы 1 типа